A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancer Chemotherapy and Pharmacology Année : 2023

A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?

Caroline Petorin
  • Fonction : Auteur
Damien Richard
  • Fonction : Auteur
Pauline Herviou
  • Fonction : Auteur
Hervé Devaud
  • Fonction : Auteur
Isabelle Creveaux
  • Fonction : Auteur
Florent Ferrer
  • Fonction : Auteur
Nicolas Authier
Marine Jary
  • Fonction : Auteur
Denis Pezet
  • Fonction : Auteur

Résumé

Abstract Purpose Irinotecan has considerable importance in the treatment of metastatic colorectal cancer (mCRC). UDP-glucoronyltransferase (UGT) 1A1 is responsible for the inactivation of SN-38, a metabolite of irinotecan. Depending on UGT1A1 polymorphism, the activity of the UGT enzyme can be reduced leading to more frequent occurrence of adverse events related to irinotecan. The present study aimed to assess the safety and efficacy of different doses of irinotecan adjusted according to UGT1A1 polymorphism. Methods Thirty-four patients treated with FOLFIRI as first-line treatment for mCRC were included in this study. The irinotecan dosage was adapted on the basis of UGT1A1 polymorphisms: *1/*1 (370 mg/m 2 ); *1/*28 (310 mg/m 2 ), and *28/*28 (180 mg/m 2 ). The incidence of grades 3 and 4 toxicities (neutropenia, febrile neutropenia, and diarrhoea) was recorded. Response was assessed according to the RECIST 1.1 criteria. Results On the basis of UGT1A1 genotyping, 20 patients were *1/*1 (58.8%), 12 were *1/*28 (35.3%) and 2 were *28/*28 (5.9%). Seven patients experienced at least one severe toxicity, i.e., 21% of the population, amounting to eleven adverse events. Concerning the response rate, 15 patients (44%) had partial or complete response. Conclusion This study demonstrates that mCRC patients treated with FOLFIRI can tolerate a higher dose of irinotecan than the standard dose, i.e., > 180 mg/m 2 , on the basis of their UGT1A1 genotype, without increased toxicities. Trial registration NCT01963182 (registered on 16/10/2013, Clermont-Ferrand, France).

Domaines

Cancer
Fichier principal
Vignette du fichier
Article IriGen_publié.pdf (739.67 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-04297253 , version 1 (24-11-2023)

Identifiants

Citer

Angeline Ginzac, Emilie Thivat, Caroline Petorin, Damien Richard, Pauline Herviou, et al.. A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?. Cancer Chemotherapy and Pharmacology, 2023, ⟨10.1007/s00280-023-04603-x⟩. ⟨hal-04297253⟩

Collections

PRES_CLERMONT
13 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More